Independent Online

Saturday, May 21, 2022

Like us on FacebookFollow us on TwitterView weather by locationView market indicators

No need yet to adapt Pfizer vaccine for Covid-19 variants: BioNTech chief

A healthcare worker receives a dose of a Pfizer-BioNTech COVID-19 vaccine at Messe Wien Congress Center, which has been set up as a coronavirus disease vaccination centre, in Vienna, Austria February 7, 2021. REUTERS/Lisi Niesner

A healthcare worker receives a dose of a Pfizer-BioNTech COVID-19 vaccine at Messe Wien Congress Center, which has been set up as a coronavirus disease vaccination centre, in Vienna, Austria February 7, 2021. REUTERS/Lisi Niesner

Published Aug 9, 2021

Share

The first generation vaccine developed by BioNTech-Pfizer works against coronavirus variants such as the Delta strain and does not need to be modified for the moment, the chief executive of German company BioNTech said Monday.

"It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case," Ugur Sahin told journalists.

Story continues below Advertisement

A decision to make a switch should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.

The fast-changing situation meant that getting the timing for the change right was also crucial.

"Making a decision at the moment might turn out to be wrong in three or six months if another variant is dominating. Therefore the timing of the decision must be appropriate," he said.

Story continues below Advertisement

"At the moment we have a good understanding that the booster vaccine with the parental strain is completely sufficient," stressed Sahin.

BioNTech's partner Pfizer has also repeatedly amplified the case for booster shots amid the latest wave of infections.

Countries including France and Germany have said they will begin offering the additional shot to the elderly and the most vulnerable from September.

Story continues below Advertisement

BioNTech-Pfizer have shipped around one billion doses of their vaccines to more than 100 countries or territories around the world.

They are expecting their annual manufacturing capacity to reach three billion doses by year's end, before climbing to four billion doses in 2022.

AFP

Story continues below Advertisement

Related Topics:

Covid-19Vaccine

Share